76 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
8 May 24
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
(1)
Research and development
Selling, general and administrative
Total operating expenses (2)
Loss from operations
Other income (expense):
Interest … :
Intangible amortization
(2) Amounts include stock-based compensation expense as follows:
Research and development
Selling, general and administrative
Total
NT 10-K
MIRM
Mirum Pharmaceuticals Inc
28 Feb 24
Notice of late annual filing
5:01pm
, partially offset by a $4.2 million decrease in research and development expense
As of December 31, 2023, Mirum had cash and cash equivalents of $286.3
8-K
EX-99.1
ka5yivlxhsyw7k3o
28 Feb 24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
tcor7respafs0yp58
2 Nov 23
Results of Operations and Financial Condition
4:06pm
8-K/A
EX-99.3
fsyx0yl2x60p
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.5
n1drqkx5whma6482o3l
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.4
qyabu3j1x
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
4xs6w4fn2e30ws1
13 Oct 23
Other Events
4:16pm
8-K
EX-10.1
rig86m1y3x
30 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
vl3eujaj
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-2.1
2cu8clhrhooh9fgh
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.1
o4m33nrrry8 g8xj
4 May 23
Results of Operations and Financial Condition
4:02pm